DCGI allows use of “Itolizumab” for moderate to severe COVID-19 cases

On July 11, 2020, the Dugs Controller General of India (DCGI) granted restricted emergency use of Itolizumab for moderate to severe COVI-19 patients.


Itolizumab is a monoclonal antibody that was already approved for chronic plaque psoriasis. The drug will now be used to treat COVID-19 based on clinical trials. The drug was manufactured and marketed by Biocon. It is an indigenous drug and has now been repurposed for COVID-19.

About the treatment

The drug is to be used to treat Cytokine Release Syndrome in COVID-19 patients that are suffering from Acute Respiratory Distress Syndrome. However, the DCGI has provided certain guidelines to use the drug such as a risk management plan, informed consent of the patient and also the drug shall be used only in hospital set up.


The average cost of treatment with the drug is lesser than comparable drugs that are part of Investigational Therapies indicated in Clinical Management Protocol for COVID-19.




Latest E-Books